ClinicalTrials.gg
RecruitingNCT04559217Updated May 27, 2026

68Ga-DOTATATE Neuroblastoma Imaging Pilot

A Phase 2 interventional study of Radiopharmaceutical 68Ga-DOTATATE in Neuroblastoma, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 3 sites in Canada. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Neuroblastoma with a site in Canada — 13 open to participants now, 28 under way, 5 of them phase 3. Neuroblastoma · Canada.

Planned enrollment
66th of 78
20 · median 90
Started
2021
with 4 others
Phase 2
27 of 88
3 open now
Primary completion
2027-12
later than 14 of 27 live
Registered
78th of 88
by date

Among the 88 studies in Neuroblastoma with a site in Canada, this one is the 66th largest by planned enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2021, is one of 27 in phase 2, reaches primary completion later than 14 of the 27 other live ones, and was the 78th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

13 of the 88 studies in Neuroblastoma with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Neuroblastoma with a site in Canada, or all of them as a file.
02

Study summary

Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.

Read the detailed description

Background: Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Initial staging of the disease and monitoring of the treatment response can be performed with different imaging modalities that include contrast-enhanced computed tomography (ceCT), ultrasound, magnetic resonance imaging (MRI), bone scintigraphy and 123I-MIBG scintigraphy.

Another potential target for neuroblastoma imaging is the somatostatin receptor (SSTR) that is present in many neuroendocrine tumours (NET). The superior PET imaging technology used with new radiotracers (such as 68Ga-DOTATATE) enables imaging at advantageous resolutions well below what is possible by current clinical SPECT systems that are used for 123I-MIBG.

Design: Prospective single-arm non-randomized clinical trial (phase II) - pilot

Objective: 1) Assess the feasibility and safety of 68Ga-DOTATATE PET/CT imaging in patients with neuroblastoma or suspected of having neuroblastoma. 2) Compare lesion-by-lesion the uptake of 68Ga-DOTATATE and 123I-MIBG in the same participant.

Study population: Children and adults with biopsy-proven or suspected neuroblastoma

Procedure and Follow-up: Few days after 123I-MIBG scan, participants will undergo a 68Ga-DOTA-cTATE PET/CT scan (duration 2 hours). Clinical data will be collected from this imaging and from the participant's medical record (demographic, treatment, medication, pathology, lab test results) for a 2-year follow-up period.

03

Conditions studied

  • Neuroblastoma

Browse trials for

Keywords

  • imaging
  • 68Ga-Dotatate
  • 68Ga-Octreotate
  • positron emission tomography (PET)
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly suspected or -proven neuroblastoma or recurrence of neuroblastoma
  • Planned 123I-MIBG imaging
  • Able and willing to provide signed in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates)
  • Aged between 1 day and 21 years old (inclusively).

Exclusion criteria

Exclusion Criteria:

  • History of another cancer in the past 5 years other than non-melanomatous skin cancer.
  • Currently under a randomized control trial with unknown allocation;
  • Currently under treatment;
  • Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan.
  • Medically unstable or unable to undergo scan.
  • Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).
  • Prior allergic reaction to somatostatin analogues
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Single arm with 68Ga-DOTATATE

    all participants will undergo a PET scan with 68Ga-DOTATATE

    Biological: Radiopharmaceutical 68Ga-DOTATATE

Interventions

  • BiologicalRadiopharmaceutical 68Ga-DOTATATE

    Injection of 68Ga-DOTATATE followed by PET/CT acquisition

06

What researchers measure

Primary outcomes

  1. Accrual rate

    Number of participants enrolled / year

    Time frame: For the duration of the study, lasting 6 years

  2. Rate of adverse events

    Number of adverse events (being serious or not) associated to the intervention (injection of 68Ga-DOTATATE and PET/CT acquisition

    Time frame: Up to 24 hours following injection of 68Ga-DOTATATE

Secondary outcomes

  1. Positive lesions for 68Ga-DOTATATE

    SUV mean of the lesion

    Time frame: One hour post-injection of 68Ga-DOTATATE

  2. Discordance of positive lesions for 68Ga-DOTATATE and positive lesions of 123I-MIBG

    the number of discordant lesions divided by the number of total positive lesions is the discordance rate

    Time frame: Within one week (period between 123I-MIBG scan and 68Ga-DOTATATE scan)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2027, 72 months after the start.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 72 months is close to that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 22, 2020
StartActual
Dec 6, 2021
Primary completionEst.
Dec 15, 2027
CompletionEst.
Sep 30, 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04559217
Lead sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Dec 6, 2021
Primary completion
Dec 15, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
May 27, 2026

Study contacts

Amelie Tetu, MSc
Contact
amelie.tetu.ciussse-chus@ssss.gouv.qc.ca
819-346-1110 ext. 15571
Etienne Rousseau, MD, FRCPC
principal investigator · CIUSSSE-CHUS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion